This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Trial of Ipilimumab After Isolated Limb Perfusion,...
Clinical trial

Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma (ILP+/-IPI)

Read time: 1 mins
Last updated:13th Mar 2014

Isolated limb perfusion (ILP) results in good response rates for locally advanced melanoma (stage IIIB and IIIC, AJCC 2009). Outcome is influenced by stage of disease, reflecting the aggressiveness of the melanoma. Our objective is to demonstrate at least a doubling of the progression free survival for the patients having an adjuvant treatment by Ipilimumab in this patient population with unfavourable characteristics. PFS ranges from 10-12 months. So at least a doubling of this period would be a clinically highly significant result.

Category Value
Study start date 2014-03-13

View full details